Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 3/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.58 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.58 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | OXTR | P30559 | 1/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228131 | 0.89 | PSEN1 (0.52) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL15675358 | 0.81 | KIF11 (0.50) | LMNAKIF11 | |
| SCHEMBL14601685 | 0.79 | MEN1 (0.65) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL8126003 | 0.77 | SCN9A (0.44) | — | |
| SCHEMBL5228000 | 0.77 | GPR119 (0.54) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL31701735 | 0.74 | PTPN2 (1.00) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL7577535 | 0.73 | CA1 (0.65) | ARCYP3A4MAPTLMNAMEN1 | |
| SCHEMBL19329626 | 0.72 | SMN1; SMN2 (0.47) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL4573249 | 0.72 | KMT2A (0.71) | ARCYP3A4MAPTMEN1ALOX15 | |
| SCHEMBL7571036 | 0.72 | CES1 (0.73) | ARMAPTMEN1ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | claimed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20050244353-A1 | Method for achieving shape memory effects on hair by combining shape memory polymers with cationic active ingredients | MNEMOSCIENCE GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050244353-A1 | Method for achieving shape memory effects on hair by combining shape memory polymers with cationic active ingredients | CD69, TES, BDNF | PTPN2 4326/4885PTPN1 4513/4885PTPN5 4542/4885 |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CCNL2, TP53, MDM2 | PTPN2 1048/4885PTPN1 1283/4885PTPN5 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.